95 related articles for article (PubMed ID: 6489764)
21. Effects of prolonged co-dergocrine mesylate (Hydergine) treatment on local cerebral glucose uptake in aged Fischer 344 rats.
Meier-Ruge W
Arch Gerontol Geriatr; 1986 Apr; 5(1):65-77. PubMed ID: 3718073
[TBL] [Abstract][Full Text] [Related]
22. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
Nobuhara K
Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
[TBL] [Abstract][Full Text] [Related]
23. The ergoloid mesylate dihydroergotoxine: radioimmunoassay measurements on plasma and blood-pressure-lowering activity.
Woodcock BG; Habedank WD; Loh W; Rietbrock N
J Cardiovasc Pharmacol; 1984; 6(3):543-5. PubMed ID: 6202984
[TBL] [Abstract][Full Text] [Related]
24. The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.
Dominiak P; Grevel J; Abisch E; Grobecker H; Dennler HJ; Welzel D
Eur J Clin Pharmacol; 1988; 35(1):53-7. PubMed ID: 3146506
[TBL] [Abstract][Full Text] [Related]
25. Co-dergocrine (hydergine) in the treatment of tardive dyskinesia.
Rastogi SC; Blowers AJ; Gibson AC
Psychol Med; 1982 May; 12(2):427-9. PubMed ID: 6124989
[TBL] [Abstract][Full Text] [Related]
26. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease.
Hartmann A
Curr Med Res Opin; 1985; 9(7):475-9. PubMed ID: 4028808
[TBL] [Abstract][Full Text] [Related]
27. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.
Thienhaus OJ; Wheeler BG; Simon S; Zemlan FP; Hartford JT
J Am Geriatr Soc; 1987 Mar; 35(3):219-23. PubMed ID: 3819261
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Neaton JD; Grimm RH; Prineas RJ; Stamler J; Grandits GA; Elmer PJ; Cutler JA; Flack JM; Schoenberger JA; McDonald R
JAMA; 1993 Aug; 270(6):713-24. PubMed ID: 8336373
[TBL] [Abstract][Full Text] [Related]
29. Renal and antihypertensive effects of co-dergocrine (Hydergine) in rats.
Siegl H
J Pharmacol; 1985; 16 Suppl 3():113-27. PubMed ID: 3912625
[TBL] [Abstract][Full Text] [Related]
30. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension.
Kirsten R; Heller A; Heintz B; Nelson K
J Hum Hypertens; 1990 Aug; 4(4):461-4. PubMed ID: 2258894
[TBL] [Abstract][Full Text] [Related]
31. Low-level lead exposure, renal function and blood pressure.
Staessen J
Verh K Acad Geneeskd Belg; 1995; 57(6):527-74. PubMed ID: 8686371
[TBL] [Abstract][Full Text] [Related]
32. Influence of co-dergocrine on platelet aggregation.
Santos RO; Rodrigues R
Braz J Med Biol Res; 1990; 23(3-4):325-7. PubMed ID: 2094545
[TBL] [Abstract][Full Text] [Related]
33. Blood pressure and hemodynamics in postmenopausal women during estradiol-17 beta substitution.
Luotola H
Ann Clin Res; 1983; 15 Suppl 38():1-121. PubMed ID: 6367617
[TBL] [Abstract][Full Text] [Related]
34. Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report.
Hajioff J; Wallace M
Psychopharmacology (Berl); 1983; 79(1):1-3. PubMed ID: 6403956
[TBL] [Abstract][Full Text] [Related]
35. Co-dergocrine mesylate (Hydergine) and hypertensive emergencies.
Romero R; Felip A; Llibre JM; Bonet J; Caralps A
Nephron; 1989; 51(1):127-8. PubMed ID: 2915745
[No Abstract] [Full Text] [Related]
36. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine.
Haller CA; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2004 Apr; 75(4):259-73. PubMed ID: 15060505
[TBL] [Abstract][Full Text] [Related]
37. Twenty-four-hour blood pressure control: effect of cilazapril on continuous arterial blood pressure during sleep, and physical and mental load in patients with arterial hypertension and sleep apnea.
Grote L; Heitmann J; Schneider H; Ploch T; Penzel T; Peter JH; von Wichert P
J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S78-82. PubMed ID: 7700072
[TBL] [Abstract][Full Text] [Related]
38. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.
Kim BH; Yi S; Kim J; Lim KS; Kim KP; Lee B; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Jun; 31(6):1234-43. PubMed ID: 19695390
[TBL] [Abstract][Full Text] [Related]
39. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
40. [Dihydroergotoxine mesylate in the treatment of senile cerebral insufficiency. Result of a long-term multicenter double-blind clinical trial with a placebo].
Lazzari R; Passeri M; Chierichetti SM
Presse Med; 1983 Dec; 12(48):3179-85. PubMed ID: 6228938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
